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2015-2016 Influenza Season 
Week 8 ending February 27, 2016 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 8 (February 21-27, 2016), influenza activity remained elevated in the 
United States. 
o Viral Surveillance: The most frequently identified influenza virus type reported by public 
health laboratories during week 8 was influenza A, with influenza A (H1N1)pdm09 viruses 
predominating. The percentage of respiratory specimens testing positive for influenza in 
clinical laboratories increased. 
o Pneumonia and Influenza Mortality: The proportion of deaths attributed to pneumonia and 
influenza (P&I) was below the system-specific epidemic threshold in the NCHS Mortality 
Surveillance System and above the system-specific epidemic threshold in the 122 Cities 
Mortality Reporting System. 
o Influenza-associated Pediatric Deaths: Four influenza-associated pediatric deaths were 
reported. 
o Influenza-associated Hospitalizations: A cumulative rate for the season of 7.8 laboratory-
confirmed influenza-associated hospitalizations per 100,000 population was reported. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 3.2%, which is above the national baseline of 2.1%. Nine of 10 regions reported ILI 
at or above region-specific baseline levels. Puerto Rico and eight states experienced high 
ILI activity; New York City and nine states experienced moderate ILI activity; 13 states 
experienced low ILI activity; 20 states experienced minimal ILI activity; and the District of 
Columbia had insufficient data. 
o Geographic Spread of Influenza: The geographic spread of influenza in Puerto Rico and 
33 states was reported as widespread; Guam and 14 states reported regional activity; the 
District of Columbia and one state reported local activity; and the U.S. Virgin Islands and two 
states reported sporadic activity. 
National and Regional Summary of Select Surveillance Components 
HHS 
Surveillance 
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Pediatric 
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Influenza test results from public health laboratories only 
Nation Elevated 19 of 53 17.6% 4,661 1,405 135 287 865 971 18 
Region 1 Normal 0 of 6 13.6% 155 33 0 19 9 19 0 
Region 2 Elevated 3 of 4 15.4% 317 124 3 31 10 24 1 
Region 3 Elevated 1 of 6 8.1% 468 48 11 20 47 25 0 
Region 4 Elevated 7 of 8 17.8% 439 125 22 17 11 153 6 
Region 5 Elevated 1 of 6 14.5% 855 117 26 14 44 16 2 
Region 6 Elevated 3 of 5 12.8% 105 127 22 17 20 56 1 
Region 7 Elevated 0 of 4 6.2% 171 39 2 7 40 9 1 
Region 8 Elevated 1 of 6 14.9% 693 65 2 30 242 26 0 
Region 9 Elevated 3 of 4 21.7% 1,142 639 35 101 255 536 6 
Region 10 Elevated 0 of 4 17.7% 316 88 12 31 187 107 1 
*http://www.hhs.gov/about/agencies/staff-divisions/iea/regional-offices/index.html 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
§ Includes all 50 states, New York City, the District of Columbia, and Puerto Rico 
‡ National data are for current week; regional data are for the most recent three weeks. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories, which include both 
public health and clinical laboratories located in all 50 states, Puerto Rico, and the District of 
Columbia, report to CDC the total number of respiratory specimens tested for influenza and the 
number positive for influenza by virus type. In addition, public health laboratories also report the 
influenza A subtype (H1 or H3) and influenza B lineage information of the viruses they test and the 
age or age group of the persons from whom the specimens were collected.   
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
The results of tests performed by clinical laboratories are summarized below. 
 
 Week 8 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 21,615 351,985 
No. of positive specimens (%) 3,803 (17.6%) 18,920 (5.4%) 
Positive specimens by type   
Influenza A 2,978 (78.3%) 13,511 (71.4%) 
Influenza B 825 (21.7%) 5,409 (28.6%) 
 
Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, 
National Summary, 2015-2016 Season 
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The results of tests performed by public health laboratories, as well as the age group distribution of 
influenza positive tests, are summarized below. 
 
 Week 8 Data Cumulative since October 4, 2015 (week 40) 
No. of specimens tested 2,008 35,705 
No. of positive specimens* 1,078 8,324 
Positive specimens by type/subtype   
Influenza A 791 (73.4%) 6,201 (74.5%) 
          A(H1N1)pmd09 707 (89.4%) 4,661 (75.2%)
          H3 72 (9.1%) 1,405 (22.7%)
          Subtyping not performed 12 (1.5%) 135 (2.2%)
Influenza B 287 (26.6%) 2,123 (25.5%) 
          Yamagata lineage 85 (29.6%) 865 (40.7%)
          Victoria lineage 40 (13.9%) 287 (13.5%)
          Lineage not performed 162 (56.4%) 971 (45.7%)
*The percent of specimens testing positive for influenza is not reported because public health laboratories often receive samples that have already tested 
positive for influenza at a clinical laboratory and therefore percent positive would not be a valid indicator of influenza activity.  Additional information is 
available at http://www.cdc.gov/flu/weekly/overview.htm 
 
Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, 
National Summary, 2015-2016 Season 
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Age Group Distribution of Influenza Positive Specimens Reported by Public 
Health Laboratories, National Summary, 2015-2016 Season 
Weekly Cumulative
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Age Group Proportions and Total by Influenza Subtype Reported by Public 
Health Laboratories, 2015-2016 Season 
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Influenza Virus Characterization: CDC characterizes influenza viruses through one or more tests 
including genome sequencing, hemagglutination inhibition (HI), and/or neutralization assays. These 
data are used to compare how similar currently circulating influenza viruses are to the reference 
viruses used for developing influenza vaccines, and to monitor for changes in circulating influenza 
viruses. Historically, HI data have been used most commonly to assess the similarity between 
reference viruses and circulating viruses to suggest how well the vaccine may work until such time 
as vaccine effectiveness estimates are available. During the 2014–2015 season and to date this 
season, however, a portion of influenza A (H3N2) viruses do not yield sufficient hemagglutination 
titers for antigenic characterization by HI. For many of these viruses, CDC performs genetic 
characterization to determine the genetic group identity of those viruses. In this way, antigenic 
properties of these viruses can be inferred from viruses within the same genetic group that have 
been characterized antigenically. 
 
CDC has characterized 783 influenza viruses [331 A (H1N1)pdm09, 251 A (H3N2), and 201 
influenza B viruses] collected by U.S. laboratories since October 1, 2015. 
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Influenza A Virus [582]  
 
 A (H1N1)pdm09 [331]:  All 331 (100%) influenza A (H1N1)pdm09 viruses were 
antigenically characterized as A/California/7/2009-like, the influenza A (H1N1) component of 
the 2015-2016 Northern Hemisphere vaccine. 
 
 A (H3N2) [251]:  All 251 H3N2 viruses were genetically sequenced and all viruses belonged 
to genetic groups for which a majority of viruses antigenically characterized were similar to 
the cell-propagated A/Switzerland/9715293/2013, the influenza A (H3N2) reference virus 
representing the 2015-2016 Northern Hemisphere vaccine component. 
o A subset of 109 H3N2 viruses also were antigenically characterized; 102 of 109 
(93.6%) H3N2 viruses were A/Switzerland/9715293/2013-like by HI testing or 
neutralization testing. 
 
Influenza B Virus [201]  
 
 Yamagata Lineage [142]: All 142 (100%) B/Yamagata-lineage viruses were antigenically 
characterized as B/Phuket/3073/2013-like, which is included as an influenza B component 
of the 2015-2016 Northern Hemisphere trivalent and quadrivalent influenza vaccines. 
 
 Victoria Lineage [59]: Fifty-eight of 59 (98.3%) B/Victoria-lineage viruses were antigenically 
characterized as B/Brisbane/60/2008-like, which is included as an influenza B component of 
the 2015-2016 Northern Hemisphere quadrivalent influenza vaccines. 
 
  
Antiviral Resistance: Testing of influenza A(H1N1)pdm09, A(H3N2), and influenza B virus isolates 
for resistance to neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir) is performed at 
CDC using a functional assay. Additional A(H1N1)pdm09 and A(H3N2) clinical samples are tested 
for mutations of the virus known to confer oseltamivir resistance. The data summarized below 
combine the results of both testing methods. These samples are routinely obtained for surveillance 
purposes rather than for diagnostic testing of patients suspected to be infected with antiviral-
resistant virus. 
 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 
A(H1N1)pdm09 and A(H3N2) viruses (the adamantanes are not effective against influenza B 
viruses). Therefore, data from adamantane resistance testing are not presented below. 
 
Neuraminidase Inhibitor Resistance Testing Results on Samples 
Collected Since October 1, 2015 
 
Oseltamivir Zanamivir Peramivir 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza 
A(H1N1)pmd09 554 2 (0.4) 363 0 (0.0) 544 2 (0.4) 
Influenza A 
(H3N2) 326 0 (0.0) 326 0 (0.0) 297 0 (0.0) 
Influenza B 321 0 (0.0) 321 0 (0.0) 321 0 (0.0) 
 
 
2015-2016 Influenza Season – Week 8, ending February 27, 2016 
 
 
The majority of recently circulating influenza viruses are susceptible to the neuraminidase inhibitor 
antiviral medications, oseltamivir, zanamivir, and peramivir; however, rare sporadic instances of 
oseltamivir-resistant and peramivir-resistant influenza A (H1N1)pdm09 viruses and oseltamivir-
resistant influenza A (H3N2) viruses have been detected worldwide. Antiviral treatment as early as 
possible is recommended for patients with confirmed or suspected influenza who have severe, 
complicated, or progressive illness; who require hospitalization; or who are at high risk for serious 
influenza-related complications. Additional information on recommendations for treatment and 
chemoprophylaxis of influenza virus infection with antiviral agents is available at 
http://www.cdc.gov/flu/antivirals/index.htm. 
 
 
 
 
 
 
 
 
Pneumonia and Influenza (P&I) Mortality Surveillance: Rapid tracking of pneumonia and 
influenza-associated deaths is done through two systems, the National Center for Health Statistics 
(NCHS) Mortality Surveillance System and the 122 Cities Mortality Reporting System. NCHS 
mortality surveillance data are presented by the week the death occurred and P&I percentages are 
released two weeks after the week of death to allow for collection of enough data to produce a 
stable P&I percentage. Users of the data should not expect the two systems to produce the same 
percentages, and the percent P&I deaths from each system should be compared to the 
corresponding system-specific baselines and thresholds. 
 
NCHS Mortality Surveillance Data:  
Based on NCHS mortality surveillance data available on March 3, 2016, 6.7% of the deaths 
occurring during the week ending February 13, 2016 (week 6) were due to P&I. This percentage is 
below the epidemic threshold of 7.7% for week 6.  
 
Region and state-specific data are available at http://www.cdc.gov/flu/weekly/nchs.htm. 
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Pneumonia and Influenza Mortality from 
the National Center for Health Statistics Mortality Surveillance System 
Data through the week ending February 13, 2016, as of March 3, 2016  
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122 Cities Mortality Reporting System 
During week 8, 7.4% of all deaths reported through the 122 Cities Mortality Reporting System were 
due to P&I. This percentage was above the epidemic threshold of 7.2% for week 8. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending February 27, 2016 
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Influenza-Associated Pediatric Mortality: Four influenza-associated pediatric deaths were 
reported to CDC during week 8.  Two deaths were associated with an influenza A (H1N1)pdm09 
virus and occurred during week 7 (the week ending February 20, 2016).  One death was associated 
with an influenza A virus for which no subtyping was performed and occurred during week 8 (the 
week ending February 27, 2016) and one death was associated with an influenza B virus and 
occurred during week 7 (the week ending February 20, 2016).   
 
A total of 18 influenza-associated pediatric deaths have been reported during the 2015-2016 
season from Puerto Rico [1], Chicago [1], and 10 states (Arizona [2], California [3], Florida [4], 
Louisiana [1], Michigan [1], Mississippi [1], Nebraska [1], Nevada [1], Tennessee [1], and 
Washington [1]). 
 
Additional data can be found at: http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
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Influenza-Associated Hospitalizations: The Influenza Hospitalization Surveillance Network 
(FluSurv-NET) conducts population-based surveillance for laboratory-confirmed influenza-related 
hospitalizations in children younger than 18 years of age (since the 2003-2004 influenza season) 
and adults (since the 2005-2006 influenza season).   
   
The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states 
(CA, CO, CT, GA, MD, MN, NM, NY, OR, and TN) and additional Influenza Hospitalization 
Surveillance Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance 
surveillance during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 
2009-2010 season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; MI, OH, RI, and UT 
during the 2011-2012 season; IA, MI, OH, RI, and UT during the 2012-2013 season; and MI, OH, 
and UT during the 2013-2014, 2014-15 and 2015-16 seasons.  
 
Data gathered are used to estimate age-specific hospitalization rates on a weekly basis, and 
describe characteristics of persons hospitalized with severe influenza illness. The rates provided 
are likely to be an underestimate as influenza-related hospitalizations can be missed, either 
because testing is not performed, or because cases may be attributed to other causes of 
pneumonia or other common influenza-related complications.  
 
Between October 1, 2015 and February 27, 2016, 2,163 laboratory-confirmed influenza-associated 
hospitalizations were reported. The overall hospitalization rate was 7.8 per 100,000 population. The 
highest rate of hospitalization was among adults aged ≥65 years (21.3 per 100,000 population), 
followed by children aged 0-4 years 11.8 per 100,000 population) and adults aged 50-64 (10.6 per 
100,000 population). Among all hospitalizations, 1,624 (75.1%) were associated with influenza A, 
505 (23.3%) with influenza B, 23 (1.1%) with influenza A and B co-infection, and 11 (0.5%) had no 
virus type information. Among those with influenza A subtype information, 545 (89.3%) were 
A(H1N1)pdm09 and 65 (10.7%) were A(H3N2) virus.  
 
Clinical findings are preliminary and based on 610 (28.2%) cases with complete medical chart 
abstraction. The majority (91.1%) of hospitalized adults had at least one reported underlying 
medical condition; the most commonly reported were cardiovascular disease, obesity and metabolic 
disorders. There were 81 hospitalized children with complete medical chart abstraction, 38 (46.9%) 
had no identified underlying medical conditions. The most commonly reported underlying medical 
conditions among pediatric patients were asthma, neurologic disorders and cardiovascular disease. 
Among the 56 hospitalized women of childbearing age (15-44 years), 15 were pregnant. 
 
Additional FluSurv-NET data can be found at: http://gis.cdc.gov/GRASP/Fluview/FluHospRates.html 
and http://gis.cdc.gov/grasp/fluview/FluHospChars.html. 
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Data from the Influenza Hospitalization Surveillance Network (FluSurv-NET), a population-based surveillance for influenza 
related hospitalizations in children and adults in 13 U.S. states. Incidence rates are calculated using the National Center 
for Health Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area. 
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FluSurv-NET data are preliminary and displayed as they become available.  Therefore, figures are based on varying 
denominators as some variables represent information that may require more time to be collected.  Data are refreshed 
and updated weekly.  Asthma includes a medical diagnosis of asthma or reactive airway disease; Cardiovascular 
diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart failure, and 
pulmonary hypertension; does not include isolated hypertension;  Chronic lung diseases include conditions such as 
chronic obstructive pulmonary disease, bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease; 
Immune suppression includes conditions such as immunoglobulin deficiency, leukemia, lymphoma, HIV/AIDS, and 
individuals taking immunosuppressive medications;  Metabolic disorders include conditions such as diabetes mellitus;  
Neurologic diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction;  
Neuromuscular diseases include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if 
indicated in patient's medical chart or if body mass index (BMI) >30 kg/m2; Pregnancy percentage calculated using 
number of female cases aged between 15 and 44 years of age as the denominator; Renal diseases include conditions 
such as acute or chronic renal failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance; No 
known condition indicates that the case did not have any known high risk medical condition indicated in medical chart at 
the time of hospitalization. 
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Outpatient Illness Surveillance: Nationwide during week 8, 3.2% of patient visits reported through 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to influenza-like 
illness (ILI). This percentage is above the national baseline of 2.1%. (ILI is defined as fever 
(temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
The increase in the percentage of patient visits for ILI in weeks 51 and 52 (the weeks ending 
December 26, 2015 and January 2, 2016) may be influenced in part by a reduction in routine 
healthcare visits during the holidays, as has occurred in previous seasons. 
 
Additional data are available at http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by 
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, 2015-2016 and Selected Previous Seasons 
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On a regional level, the percentage of outpatient visits for ILI ranged from 1.2% to 4.2% during 
week 8. Nine regions (Regions 2, 3, 4, 5, 6, 7, 8, 9, and 10) reported a proportion of outpatient visits 
for ILI at or above their region-specific baseline levels.   
 
 
 
 
 
2015-2016 Influenza Season – Week 8, ending February 27, 2016 
 
 
Region 1 - CT, ME, MA, NH, RI, VT
0
2
4
6
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 6 - AR, LA, NM, OK, TX
0
2
4
6
8
10
12
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 3 - DE, DC, MD, PA, VA, WV
0
2
4
6
8
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 4 - AL, FL, GA, KY, MS, NC, SC, TN
0
2
4
6
8
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 5 - IL, IN, MI, MN, OH, WI
0
2
4
6
8
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 7 - IA, KS, MO, NE
0
2
4
6
8
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 8 - CO, MT, ND, SD, UT, WY
0
2
4
6
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 9 - AZ, CA, HI, NV
0
2
4
6
8
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 10 - AK, ID, OR, WA
0
2
4
6
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
Region 2 - NJ, NY, PR, USVI
0
2
4
6
20
13
40
20
13
50
20
14
10
20
14
20
20
14
30
20
14
40
20
14
50
20
15
10
20
15
20
20
15
30
20
15
40
20
15
50
Week
%
 o
f V
is
its
 fo
r I
L
% ILI Baseline*NOTE: Scales differ between regions
*Use of the regional baselines for state data is not appropriate. 
 
2015-2016 Influenza Season – Week 8, ending February 27, 2016 
 
 
ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during weeks with little or no 
influenza virus circulation. Activity levels range from minimal, which would correspond to ILI activity 
from outpatient clinics being below, or only slightly above, the average, to high, which would 
correspond to ILI activity from outpatient clinics being much higher than average. 
 
During week 8, the following ILI activity levels were experienced: 
 Puerto Rico and eight states (Arizona, Arkansas, Illinois, Maryland, New Mexico, North 
Carolina, Tennessee, and Utah) experienced high ILI activity. 
 New York City and nine states (Alabama, California, Florida, Hawaii, Kentucky, Mississippi, 
New Jersey, Oklahoma, and South Carolina) experienced moderate ILI activity. 
 13 states (Colorado, Georgia, Indiana, Kansas, Louisiana, Michigan, Minnesota, Missouri, 
New York, Oregon, Pennsylvania, Texas, and Virginia) experienced low ILI activity. 
 20 states (Alaska, Connecticut, Delaware, Idaho, Iowa, Maine, Massachusetts, Montana, 
Nebraska, Nevada, New Hampshire, North Dakota, Ohio, Rhode Island, South Dakota, 
Vermont, Washington, West Virginia, Wisconsin, and Wyoming) experienced minimal ILI 
activity. 
 Data were insufficient to calculate an ILI activity level from the District of Columbia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of flu within a state. Therefore, outbreaks occurring in a single city 
could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial flu activity map is based on reports 
from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete. 
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the severity of influenza activity. 
  
During week 8, the following influenza activity was reported: 
 Widespread influenza activity was reported by Puerto Rico and 33 states (Alaska, Arizona, 
California, Connecticut, Delaware, Idaho, Iowa, Kansas, Kentucky, Maryland, 
Massachusetts, Michigan, Minnesota, Montana, Nebraska, Nevada, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Pennsylvania, Rhode 
Island, South Dakota, Texas, Utah, Vermont, Virginia, Washington, Wisconsin, and 
Wyoming). 
 Regional influenza activity was reported by Guam and 14 states (Alabama, Arkansas, 
Colorado, Florida, Georgia, Hawaii, Illinois, Indiana, Louisiana, Maine, Missouri, Oklahoma, 
South Carolina, and Tennessee). 
 Local influenza activity was reported by the District of Columbia and one state (Mississippi). 
 Sporadic influenza activity was reported by the U.S. Virgin Islands and two states (Oregon 
and West Virginia).  
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Additional National and International Influenza Surveillance Information 
 
FluView Interactive: FluView includes enhanced web-based interactive applications that can provide 
dynamic visuals of the influenza data collected and analyzed by CDC. These FluView Interactive applications 
allow people to create customized, visual interpretations of influenza data, as well as make comparisons 
across flu seasons, regions, age groups and a variety of other demographics. To access these tools, visit 
http://www.cdc.gov/flu/weekly/fluviewinteractive.htm. 
 
U.S. State, territorial, and local influenza surveillance: Click on a jurisdiction below to access the latest 
local influenza information. 
 
Alabama Alaska Arizona Arkansas California 
Colorado Connecticut Delaware District of Columbia Florida 
Georgia Hawaii Idaho Illinois Indiana 
Iowa Kansas Kentucky Louisiana Maine 
Maryland Massachusetts Michigan Minnesota Mississippi 
Missouri Montana Nebraska Nevada New Hampshire 
New Jersey New Mexico New York North Carolina North Dakota 
Ohio Oklahoma Oregon Pennsylvania Rhode Island 
South Carolina South Dakota Tennessee Texas Utah 
Vermont Virginia Washington West Virginia Wisconsin 
Wyoming New York City Puerto Rico U.S. Virgin Islands 
 
 
World Health Organization: Additional influenza surveillance information from participating WHO member 
nations is available through FluNet and the Global Epidemiology Reports. 
 
WHO Collaborating Centers for Influenza located in Australia, China, Japan, the United Kingdom, and the 
United States (CDC in Atlanta, Georgia). 
 
Europe: For the most recent influenza surveillance information from Europe, please see WHO/Europe and 
the European Centre for Disease Prevention and Control at http://www.flunewseurope.org/  
 
Public Health Agency of Canada: The most up-to-date influenza information from Canada is available at 
http://www.phac-aspc.gc.ca/fluwatch/. 
 
Public Health England: The most up-to-date influenza information from the United Kingdom is available at 
https://www.gov.uk/government/statistics/weekly-national-flu-reports.  
 
Any links provided to non-Federal organizations are provided solely as a service to our users. These links do not 
constitute an endorsement of these organizations or their programs by CDC or the Federal Government, and 
none should be inferred. CDC is not responsible for the content of the individual organization web pages found 
at these links. 
 
An overview of the CDC influenza surveillance system, including methodology and detailed 
descriptions of each data component, is available at: http://www.cdc.gov/flu/weekly/overview.htm.  
 
 
Report prepared: March 4, 2016. 
 
 
 
 
 
